Kishu Ranjan
1*
Prabhatchandra Dube
2
Sandeep Kumar Mishra
1The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Med.
Sec. Precision Medicine
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1452812
This article is part of the Research Topic Engineered Medicines to Mitigate Resistances to Cancer Immunotherapy View all 7 articles
Editorial: Engineered Medicines to Mitigate Resistances to Cancer Immunotherapy
Provisionally accepted- 1 Yale University, New Haven, United States
- 2 University of Toledo, Toledo, Ohio, United States
Keywords: cancer immunotherapy, tumor immunology, Engineered Medicines, CAR-T cells, personalized therapy
Received: 21 Jun 2024; Accepted: 17 Jul 2024.
Copyright: © 2024 Ranjan, Dube and Mishra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kishu Ranjan, Yale University, New Haven, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.